Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : 2022 Biotech Charity Contest -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (98)	3/14/2022 2:10:28 PM
From: technetium	Respond to of 267

I first watched INHL for inhaled insulin, but early reports implied clinical indications of generating anti-insulin antibodies, which could be a death knell for diabetics. Didn’t pay close attention to how the cookie crumbled. The headlines for NKTR at the time (April, 2008) weren’t promising, as it apparently included an increase in lung cancer: Nektar Gives Up on Inhaled Insulin Latest study data serve as the death knell for the Exubera program, and also send shares of competitor Mannkind lower. thestreet.com Yes, the increase in lung cancer may have been greater amongst smokers, but if smoking correlates with a lifestyle that may lead to diabetes, then it’s part of the consideration.